Información del artículo
El Texto completo está disponible en PDF
Referencias Bibliográficas
[1.]
Agwunobi T.C., Boak J.L..
Diagnosis of malignant breast disease by axillary lymphoscintigraphy: A preliminary report.
Br J Surg, 65 (1978), pp. 379-383
[2.]
Lin P.P., Allison D.C., Wainstock J., Miller K.D., Dooley W.C., Friedman N., et al.
Impact of axilary lymph node dissection on the therapy of breast cancer patients.
J Clin Oncol, 11 (1993), pp. 1536-1544
[3.]
Reintgen D..
What is the role and impact of the sentinel node sampling technique in breast cancer staging?.
Cancer Control: JMCC, 4 (1997), pp. 5-8
[4.]
Veronesi U., Galimberti V., Zurrida S., Merson M., Greco M., Luini A..
Prognostic significance of number and level of axillary node metastases in breast cancer.
The Breast, 2 (1993), pp. 224-228
[5.]
Veronesi U., Salvadori B., Luini A., Greco M., Saccozzi R., del Vecchio M., et al.
Breast conservation is a safe method in patients whit small cancer of the breast. Long-term results of three randomised trials on 1.973 patients.
Eur J Cancer, 31A (1995), pp. 1574-1579
[6.]
Baxter N., McCready D., Chapman J.A., Fish E., Kahn H., Hanna W., et al.
Clinical behaviour of untreatad axillary nodes after local treatment for primary breast cancer.
Ann Surg Oncol, 3 (1996), pp. 235-240
[7.]
Giuliano A.E..
Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary disection (editorial).
J Surg Oncol, 62 (1996), pp. 75-77
[8.]
Della Rovere G., Bird P.A..
Sentinel-lymph-node in breast cancer.
Lancet, 352 (1998), pp. 421-422
[9.]
Keshtgar M.R.S., Ell P.J..
Sentinel lymph node detection and imaging.
Eur J Nucl Med, 26 (1999), pp. 57-67
[10.]
Uren R.F., Howman-Giles R.B., Thompson J.F., Malouf D., ramsey-Stewart G., Niesche F.W., Renwick S.B..
Mammary lymphoscintigraphy in breast cancer.
J Nucl med, 36 (1995), pp. 1775-1780
[11.]
Albertini J.J., Lyman G.H., Cox C., Yeatman T., et al.
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.
J Am Med Assoc., 276 (1996), pp. 1818-1822
[12.]
De Cicco C., Paganelli G., Cremonesi M., Galimberti V., Bartolomei M., Viale G., et al.
Gamma-probe guided resection of the sentinel node in breast cancer.
Eur J Nucl Med., 24 (1997), pp. 892
[13.]
Tiourina T., Arends B., Huysmans D., Rutten H., Lemaire B., Muller S..
Evaluation of surgical gamma probes for radioguided sentinel node localisation.
Eur J Nucl Med., 25 (1998), pp. 1224-1231
[14.]
Nwariaku F.E., Euhus D.M., Beistch P.D., Cliford E., Erdman C.E., Mathews D., et al.
Sentinel lymph node biopsy, an alternative to elective axillarydi section for breast cancer.
Am J Surg, 176 (1998), pp. 529-531
[15.]
Borgstein P.J., Pijpers R., Comans E.F., Van Diest P.J., Boom R.P., Meijer S..
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gammaa probe detection.
J Am Coll Surg., 186 (1998), pp. 275-283
[16.]
Veronesi U., Paganelli G., Viale G., Galimberti V..
Sentinel Lymph Node biopsy and axillary Dissection in breast cancer: results in a large series.
J Natl Cancer Inst, 91 (1999), pp. 368-373
[17.]
Krag D.N., Weaver D., Ashikaga T., Moffat F., Klimberg V.S., Sheiner C., et al.
The sentinel node in breast cancer. A multicenter validation study.
N Engl J Med, 339 (1998), pp. 941-946
[18.]
Winchester D.J., Sener S.F., Winchester D.P., Perlman R.M., Goldschmidt R.A., Morykie G., et al.
Sentinel lymphadenectomy for breast cancer: experience with 180 consecutive patients: efficacy of filtered tecnetium 99m sulphur colloid with overnight migration time.
J Am Coll Surg, 188 (1999), pp. 597-603
[19.]
Jaderborg J.M., Harrison P.B., Kiser J.L., Maynard S.L..
The feasibility and accuracy of the sentinel lymph node biopsy for breast carcinoma.
Am Surg, 65 (1999), pp. 699-705
[20.]
Miner T.J., Schiver C.D., Jaques D.P., Meniscalco M.E., Krag D.N..
Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient elegibility.
Am Surg, 65 (1999), pp. 493-499
[21.]
Fraile M., Rull M., Julian F.J., Fusté F., Barnadas A., Llatjós M., et al.
Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: An approach to its validity.
Ann Oncol, 11 (2000), pp. 701-705
[22.]
Prats E., Carril J.M., Herranz R., Meroño E., Banzo J., GTEMEGMMT.
Spanish multicenter study. MIBI-99m Tc breast scans. Report of results.
Rev Esp Med Nucl., 5 (1998), pp. 338-350
[23.]
Taillefer R..
Breast Scintigraphy. Chapter 73.
Murray& Ell: Nuclear Medicine in Clinical Diagnosis and Treatment, Second, Churchill Livingstone publishers, (1998),
[24.]
Waxman A.D..
The role of 99m Tc methoxyisobutylisonitrile in imaging breast cancer.
Semin Nucl Med, 27 (1997), pp. 40-54
[25.]
Khalkhali I., Cutrone J.A., Mena I.G., Diggles L.E., Venegas R.J., Vargas H.I., Jackson B.L., Khalkhali S., Moss J.F., Klein S.R..
Scintimammography: the complementary role of Tc-99m SestaMIBI prone breast imaging for the diagnosis of breast carcinoma.
Radiology, 196 (1995), pp. 421-426
[26.]
Khalkhali I., Villanueva-Meyer S., Edell L., Hanelin L.G., Lugo C.E., Taillefer R., et al.
Diagnostic accuracy of Tc-99m sestamibi breast imaging in breast cancer detection.
J Nucl Med., 37 (1996), pp. 74
[27.]
Lu G., Shih W.J., Huang H.Y., et al.
99m Tc-MIB Imammo-scintigraphy of breast masses: earlyand delayed imaging.
Nucl Med Commun., 16 (1995), pp. 150-156
[28.]
Palmedo H., Schomburg A., Grunwald F., et al.
Technetium-99m-MIBI scintimammography for suspicious breast lesions.
J Nucl Med, 37 (1996), pp. 626-630
[29.]
Burak Z., Argon M., Memis A., et al.
Evaluation of breast masses with 99mTc-MIBI: a comparative study with mammography and ultrasonography.
Nucl Med Commun, 15 (1994), pp. 604-612
[30.]
Kao C., Wang S., Liu T..
The use of TC99m methoxybutyl-isonitrile breast scintigraphy to evaluate palpable breast masses.
Eur J Nucl Med, 21 (1994), pp. 432-436
[31.]
Taillefer R..
The role of 99m-Tc-Sestamibi and other convectional radiopharmaceuticals in breast cancer diagnosis.
Sem Nucl Med XXIX, 1 (1999), pp. 16-40
[32.]
Taillefer R., Robidoux A., Lambert R., et al.
Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axi-llary lymph node involvement.
J Nucl Med, 36 (1995), pp. 1758-1765
[33.]
Maublant J., de Latour M., Metas D., et al.
Technetium-99m-Sestamibi Uptake in Breast Tumor and Associated Lymph nodes.
J Nucl Med, 37 (1996), pp. 922-925
[34.]
Lam W.W.M., Yang W.T., Chan Y.L., et al.
Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography.
Eur J Nucl Med, 23 (1996), pp. 498-503
[35.]
Schillaci O., Scopinaro F., Danieli R., et al.
Technetium-99m Sestamibi Imaging in the Detection of Axillary Lymph Node Involvement in Patients with Breast Cancer.
Anticancer Research, 17 (1997), pp. 1607-1610
[36.]
Perre C.I., Rutter J.E., Vos P.A.F.M., et al.
Technetium-99m-sestamibi uptake in axillary lymph node metastases in breast cancer patients.
Eur J Surg Oncol., 23 (1997), pp. 142-144
[37.]
Taillefer R., Robidoux A., Turpin S., et al.
Metastasic Axillary Lymph Node Technetium-99m-MIBI Imaging in Primary Breast Cancer.
J Nucl Med., 39 (1998), pp. 459-464
[38.]
Picwnica-Worms Chiu M.L., Budding M., Kronagne J.F., Kramer R.A., Croop L.M..
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Cancer Res, 53 (1993), pp. 977-984
[39.]
Palmedo H., Biersack H.J., Lastoria S., Maublant J., Prats E..
Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial.
Eur J Nucl Med, 25 (1998), pp. 375-385
[40.]
Minn H..
Soini I. [18F] fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer.
Eur J Nucl Med, 15 (1989), pp. 61-66
[41.]
Whal R.l., Cody R., Hutchins G.D., Mudgett E..
Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabelled glucose analog 2-(F-18)-fluoro-deoxy-2-D-glucose (FDG).
Radiology, 179 (1991), pp. 765-770
[42.]
Nieweg O.E., Kim E.E., Wong W.H., Broussard W.F., et al.
Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
Cancer, 71 (1993), pp. 3920-3925
[43.]
Avril N., Dose J., Janicke F., Bense S., Ziegler S., Laubenbacher C., Romer W., Pache H., Herz M., Allgayer B., et al.
Metabolic characterization of breast tumors with positron emision tomography using F-18 fluorodeoxyglucose.
J Clin Onc, 14 (1996), pp. 1848-1857
[44.]
Scheidhauer K., Scharl A., Pietrzyk U., Wagner R., Gohring U.J., Schomacker K., Schicha H..
Qualitative [18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Eur J Nucl Med, 23 (1996), pp. 618-623
[45.]
Crippa F., Agresti R., Seregni E., Greco M., et al.
Prospective valuation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
J Nucl Med, 39 (1998), pp. 4-8
[46.]
Moon D., Silverman D., Maddahi J., Glaspy J., et al.
Accuracy of whole body FDG PET for the detection of recurrent or metastasic breast carcinoma.
J Nucl Med, 39 (1998), pp. 431-435
[47.]
Tse N.Y., Hoh C.K., Hawkins R.A., et al.
The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.
Ann Surg, 216 (1992), pp. 27-34
[48.]
Adler L.P., Crowe J.P., Al-Kasi N.K., Sunshine J.L..
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Radiology, 187 (1993), pp. 743-750
[49.]
Utech C.I., Young C.S., Winter P.F..
Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Eur J Nucl Med, 23 (1996), pp. 1588-1593
[50.]
Adler L.P., Faulhaber P.F., Schnur K.C., Al-Kasi N.L., et al.
Axillary lymph node metastases: screening with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Radiology, 203 (1997), pp. 323-327
[51.]
Goldenberg D.M., Larson S.M..
Radioinmmunodetection in cancer identificacion.
J Nucl Med, 33 (1992), pp. 803-814
[52.]
Nabi H.A..
Antibody imaging in breast cancer.
Sem Nucl Med, 27 (1997), pp. 30-39
[53.]
Goldenberg D.M., De L.F., Kim E., et al.
Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.
N Eng J Med., 298 (1978), pp. 1384-1388
[54.]
Rosner D., Nabi H., Wild L., Ortman-Nabi J., Hreshchyshyn M.M..
Diagnosis of breast carcinoma with radiolabeled monoclonal antibodies (MoAbs) to carcinoembryonic antigen (CEA) and human milk fat globulin (HMFG).
Cancer Invest, 13 (1995), pp. 573-582
[55.]
Buraggi G.L., Serogni E..
Radio inmmunodetection of tumors with radiolabelled monoclonal antibodies: basic aspects and clinical applications.
Clinical applications of radiolabelled antibodies in oncology, pp. 9-35
[56.]
Esteban J.M., Felder B., Ahn C., Simpson J.F., Battifora H., Shively J.E..
Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Cancer, 74 (1994), pp. 1575-1583
[57.]
Lind P., Smola M.G., Lechner P., et al.
The inmmunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastasic breast cancer.
Int J Cancer, 47 (1991), pp. 865-869
[58.]
Sledge Jr G.W..
Implications of the new biology for therapy in breast cancer.
Semin Oncol, 23 (1996), pp. 76-81
[59.]
Kramer E.L., DeNardo S.J., Liebes L., et al.
Radioimmuno-localization of breast cancer using BrE-3 monoclonal antibody.
Adv Exp Med Biol, 353 (1994), pp. 181-192
[60.]
Schrier D.M., Stemmer S.M., Johnson T..
High dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
Cancer Res, 55 (1995), pp. 5921-5924
[61.]
Ozzello L., Blank E.W., De Rosa C.M., et al.
Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts.
Breast CancerRes Treat, 48 (1998), pp. 135-147
[62.]
Buckman R., De Angelis C., Shaw P., et al.
Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3.
Gynecol Oncol, 47 (1992), pp. 102-109
[63.]
DeNardo S.J., O'Grady L.F., Richman C.M., et al.
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
Anticancer Res, 17 (1997), pp. 1745-1751
[64.]
Griffiths G.L., Goldenberg D.M., Roesch F., Hansen H.J..
Radiolabeling of an anti-carcino-embryonic antigen antibody Fab'fragment (CEA-Scan®) with the positron-emitting radionuclide, Tc-94m.
Cancer Biother Radiopharm, 13 (1998), pp. 318
Copyright © 2000. Academia de Ciencias Médicas de Bilbao